ResearchMoz

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

GBI Research
Published Date » 2014-01-31
No. Of Pages » 120
   
 GBI Research, has released the pharma report – “Hepatitis C Therapeutics in Major Developed Markets to 2019 – Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape”. The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales. However, these products are very poorly tolerated and only moderately efficacious. The approval of the DAA Sovaldi in December 2013 changed this, with a complete viral clearance...
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Signs and Symptoms
2.2 Etiology and Risk Factors
2.3 Pathophysiology
2.4 Epidemiology
2.4.1 US and Canada
2.4.2 Europe
2.4.3 Japan
2.4.4 Regional Prevalence of Hepatitis C Genotypes
2.5 Prognosis
2.6 Diagnosis and Screening
2.7 Treatment
2.8 Treatment Algorithms

3 Marketed Products
3.1 Ribavirin
3.2 Pegasys (Peginterferon alfa 2a) and PegIntron (Peginterferon alfa 2b) – Hoffmann La Roche and Merck & Co
3.2.1 Pegasys – Hoffmann La Roche
3.2.2 PegIntron – Merck & Co
3.3 Incivek (telaprevir) – Vertex Pharmaceuticals and Janssen-Cilag
3.4 Victrelis (boceprevir) – Merck & Co
3.5 Olysio (simeprevir) – Johnson and Johnson
3.6 Sovaldi (sofosbuvir) – Gilead Sciences
3.7 Heat Map for Marketed Products

4 Developmental Pipeline
4.1 Overall Pipeline
4.2 Mechanisms of Action
4.3 Clinical Trials
4.3.1 Clinical Trial Failure Rates
4.3.2 Clinical Trial Enrollment
4.3.3 Clinical Trial Duration
4.3.4 Clinical Trial Design
4.4 Promising Pipeline Drugs
4.4.1 Sovaldi plus Ledipasvir – Gilead Sciences
4.4.2 Daclatasvir – Bristol-Myers Squibb
4.4.3 Faldaprevir – Boehringer-Ingelheim
4.4.4 Peginterferon lambda 1a – Bristol-Myers Squibb
4.4.5 ABT-450 – AbbVie and Enanta
4.4.6 Vaniprevir – Merck & Co
4.5 Heat Map and Competitor Matrix for Pipeline Products
4.6 Conclusion

5 Market Forecast to 2019
5.1 Global Market
5.1.1 Treatment Usage Patterns
5.1.2 Market Size
5.2 US
5.2.1 Treatment Usage Patterns
5.2.2 Market Size
5.3 Canada
5.3.1 Treatment Usage Patterns
5.3.2 Market Size
5.4 Top Five European Markets
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Usage Patterns
5.5.2 Market Size

6 Drivers and Barriers
6.1 Drivers
6.1.1 Approval of Sovaldi and Olysio in 2013
6.1.2 Large and Exceptionally Promising Late-Stage Pipeline
6.1.3 Favorable Pricing Structure in the US
6.1.4 Weak Exposure to Generics and Biosimilars during the Forecast Period
6.1.5 Increasing Volume of Treated Patients
6.1.6 Rapid Incorporation of Novel Products into Treatment Guidelines
6.2 Barriers
6.2.1 Low Rates of Diagnosis and Treatment in Certain Markets
6.2.2 Unfavorable Pricing Structures in the EU and Japan
6.2.3 Rapidly Increasing Competition in the Market

7 Licensing and Co-development deals
7.1 Licensing Deals
7.1.1 Vertex Pharma Enters into Licensing Agreement with Alios BioPharma for ALS-2200 and ALS-2158
7.1.2 Bristol-Myers Squibb Company Enters into Licensing Agreement with ZymoGenetics
7.1.3 Human Genome Sciences Enters Into Licensing Agreement With Novartis
7.1.4 Roche Signs Licensing Agreement With InterMune
7.1.5 Idenix Enters Into A Licensing Agreement With Novartis Pharma
7.1.6 Enanta Pharma Enters into Licensing Agreement with Novartis for Hepatitis C Program
7.1.7 Medivir Enters into Licensing Agreement with Tibotec
7.1.8 Metabasis Therapeutics Enters Into Collaboration And Licensing Agreement With Roche
7.1.9 Schering-Plough And PTC Therapeutics Enter Into A Collaboration And Licensing Agreement
7.1.10 Presidio Pharma Enters into Licensing Agreement with XTL BioPharma
7.2 Co-development Deals
7.2.1 Vertex Pharma Enters into Co-Development Agreement with Janssen Pharmaceutica
7.2.2 Abbott Labs Enters into Agreement with Enanta Pharma
7.2.3 Genelabs Enters into Collaboration with Novartis
7.2.4 Regulus Therapeutics Enters into an Agreement with GlaxoSmithKline
7.2.5 Tacere Therapeutics Enters into Agreement with Pfizer
7.2.6 Biota Holdings Enters into an Agreement with Boehringer Ingelheim

8 Appendix
8.1 Sources
8.2 Sources for Heat Maps
8.3 All Pipeline Products, by Stage of Development
8.3.1 Discovery
8.3.2 Preclinical and IND/CTA-filed
8.3.3 Phase I
8.3.4 Phase II
8.3.5 Phase III and Pre-registration
8.3.6 Undisclosed
8.4 Tabular Forecast Data
8.4.1 Global
8.4.2 US
8.4.3 Canada
8.4.4 UK
8.4.5 France
8.4.6 Germany
8.4.7 Italy
8.4.8 Spain
8.4.9 Japan
8.5 Market Definition
8.6 Abbreviations
8.7 Methodology
8.7.1 Coverage
8.7.2 Secondary Research
8.7.3 Primary Research
8.7.4 Therapeutic Landscape
8.7.5 Epidemiology-Based Forecasting
8.7.6 Market Size by Geography
8.7.7 Geographical Landscape
8.7.8 Pipeline Analysis
8.8 Contact Us
8.9 Disclaimer

List of Tables

Table 1: Hepatitis C, Top Five European Countries, Disease Prevalence (%), 2011
Table 2: Hepatitis C, Top Five European Markets, Most Common Risk Factors for Infection (%), 2011
Table 3: Hepatitis C, Global, Estimated Distribution of Hepatitis C Genotypes (%), 2013
Table 4: Market for Hepatitis C, Sources for Heat Maps
Table 5: Hepatitis C Therapeutics, Global, All Pipeline Products (Discovery), 2013
Table 6: Hepatitis C Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013
Table 7: Hepatitis C, Global, All Pipeline Products (Phase I), 2013
Table 8: Hepatitis C Therapeutics, Global, All Pipeline Products (Phase II), 2013
Table 9: Hepatitis C Therapeutics, Global, All Pipeline Products (Phase III), 2013
Table 10: Hepatitis C Therapeutics, Global, All Pipeline Products (Undisclosed), 2013
Table 11: Market for Hepatitis C, Global, Forecast Data, 2012–2019
Table 12: Market for Hepatitis C, US, Forecast Data, 2012–2019
Table 13: Market for Hepatitis C, Canada, Forecast Data, 2012–2019
Table 14: Market for Hepatitis C, UK, Forecast Data, 2012–2019
Table 15: Market for Hepatitis C, France, Forecast Data, 2012–2019
Table 16: Market for Hepatitis C, Germany, Forecast Data, 2012–2019
Table 17: Market for Hepatitis C, Italy, Forecast Data, 2012–2019
Table 18: Market for Hepatitis C, Spain, Forecast Data, 2012–2019
Table 19: Market for Hepatitis C, Japan, Forecast Data, 2012–2019

List of Figures

Figure 1: Market for Hepatitis C, Global, Treatment Algorithm (Genotype 1, Triple Therapy with Incivek), 2013
Figure 2: Market for Hepatitis C, Global, Treatment Algorithm (Genotype 1, Triple Therapy with Victrelis), 2013
Figure 3: Market for Hepatitis C, Global, Treatment Algorithm (Genotypes 2 to 7), 2013
Figure 4: Market for Hepatitis C, Global, Sales of Pegasys and PegIntron ($m), 2002–2012
Figure 5: Market for Hepatitis C, Global, Heat Map for Marketed Products, 2013
Figure 6: Market for Hepatitis C, Global, Developmental Pipeline, 2013
Figure 7: Market for Hepatitis C, Global, Pipeline by Mechanism of Action and Molecule Type, 2013
Figure 8: Market for Hepatitis C, Global, Clinical Trial Failure Rate by Molecule Type, 2006–2013
Figure 9: Market for Hepatitis C, Global, Clinical Trial Failure Rates by Mechanism of Action, 2006–2013
Figure 10: Market for Hepatitis C, Global, Clinical Trial Enrollment by Molecule Type, 2006–2013
Figure 11: Market for Hepatitis C, Global, Clinical Trial Enrollment by Mechanism of Action, 2006–2013
Figure 12: Market for Hepatitis C, Clinical Trial Duration by Molecule Type, 2006–2013
Figure 13: Market for Hepatitis C, Global, Clinical Trial Duration by Mechanism of Action, 2006–2013
Figure 14: Market for Hepatitis C, Global, Frequency of Clinical Trial Primary Endpoints Per Clinical Trial, 2006–2013
Figure 15: Market for Hepatitis C, Global, Frequency of Clinical Trial Endpoints Primary within Clinical Development Programs, 2006–2013
Figure 16: Market for Hepatitis C, Global, Usage of HCV Genotypes as Clinical Trial Inclusion Criteria, 2006–2013
Figure 17: Market for Hepatitis C, Global, Sales Forecast for Sovaldi plus ledipasvir ($m), 2015–2019
Figure 18: Market for Hepatitis C, Global, Sales Forecast for daclatasvir (monotherapy) ($m), 2015–2019
Figure 19: Market for Hepatitis C, Global, Sales Forecast for daclatasvir plus asunaprevir plus BMS-791325 ($m), 2015–2019
Figure 20: Market for Hepatitis C, Global, Sales Forecast for faldaprevir ($m), 2015–2019
Figure 21: Market for Hepatitis C, Global, Sales Forecast for peginterferon lambda 1a ($m), 2015–2019
Figure 22: Market for Hepatitis C, Global, Sales Forecast for ABT-450 ($m), 2015–2019
Figure 23: Market for Hepatitis C, Global, Sales Forecast for ABT-450 plus ABT-333 plus ABT-267 ($m), 2015–2019
Figure 24: Market for Hepatitis C, Global, Sales Forecast for vaniprevir, 2015–2019
Figure 25: Market for Hepatitis C, Global, Heat Map for Pipeline Products, 2013
Figure 26: Market for Hepatitis C, Global, Competitor Matrix, 2013
Figure 27: Market for Hepatitis C, Global, Market Growth and Size, 2012–2019
Figure 28: Market for Hepatitis C, Global, Treatment Patterns, 2012–2019
Figure 29: Market for Hepatitis C, Global, Market Size ($bn), 2012–2019
Figure 30: Market for Hepatitis C, US, Treatment Usage Patterns, 2012–2019
Figure 31: Market for Hepatitis C, US, Market Size ($bn), 2012–2019
Figure 32: Market for Hepatitis C, Canada, Treatment Usage Patterns, 2012–2019
Figure 33: Market for Hepatitis C, Canada, Market Size ($m), 2012–2019
Figure 34: Market for Hepatitis C, Top Five European Markets, Treatment Patterns, 2012–2019
Figure 35: Market for Hepatitis C, Top Five European Markets, Annual Cost of Therapy ($), 2012–2019
Figure 36: Market for Hepatitis C, Top Five European Markets, Market Size ($m), 2012–2019
Figure 37: Market for Hepatitis C, Japan, Treatment Usage Patterns, 2012–2019
Figure 38: Market for Hepatitis C, Japan, Market Size ($m), 2012–2019
Figure 39: Market for Hepatitis C, Global, Network of Licensing Deals, 2006–2013
Figure 40: Market for Hepatitis C, Global, Licensing Deals by Year, 2006–2013
Figure 41: Market for Hepatitis C, Global, Licensing Deals, 2006–2013
Figure 42: Market for Hepatitis C, Global, Network of Co-Development Deals, 2006–2013
Figure 43: Market for Hepatitis C, Global, Co-Development Deals by Year, 2006–2013
Figure 44: GBI Research Market Forecasting Model

Upcoming Reports:

Actinic Keratosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
Presence of thick, crusty or scaly patches on the skin surface indicating premalignant condition is referred as actinic keratosis. People who are commonly exposed to sun light are at higher risk of actinic keratosis. Thus, actinic keratosis is commonly found in people who have fair skin. Thus, prevalence of actinic keratosis is higher in western countries than in Asian countries. Commonly, progression of actinic keratosis leads to squamous cell carcinoma. Squamous cell carcinoma is a type of cancer with lesser risk to life if treated early. Thus, early treatment of actinic keratosis is...
U.V. Cure Resins Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
UV curing refers to a way of radiation curing by which various materials are cured which includes inks, coatings and adhesives among others. UV curing technology is a technology which enables instant drying or curing in fraction of seconds when ultraviolet light is applied on various products such as coatings, inks and adhesives among others to cause photopolymerisation. Along with advances in technology, various types of resins are now available in the market owing to advantages which includes reducing wastes, saving energy, low temperature treatment and high productivity. Moreover, UV is...
Personalized Medicines Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
The US market for personalized medicines is predicted to grow at the compounded annual growth rate of 9.5% during 2010 to 2015. This growth in future is expected to be driven by different factors like cost savings on treatments, early diagnosis of disease, drug safety, patient compliance, and optimization of therapies. Currently, America dominates the market for personalized medicine; however, advancement in technology and developments in the field of DNA is expected to establish personalized medicines market in UK, France, India, China, and Japan.  Developments in...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Regulators Requesting a Broad Range of Communication Records
May 29, 2015  
Regulators are growingly requesting a broader range of communication records from organizations while conduction a regulatory test/exam. Email continues to be the most commonly requested record for communication; however, this trend is quickly changing. Around 77 percent of advisors state that the regulators have requested email data during a latest examination, states the...
Food and Wine Festival of Atlanta Makes a Grand Opening on 28th May
May 28, 2015  
A food festival, which has been nationally renowned, and has its headquarters at the Loews Atlanta Hotel in the Midtown, is all set to open on 28th of May. This event is expected to bring around thousands of people to this area in order to explore the authentic Southern beverage and food traditions. This will cover the entire region starting from Texas to Washington D.C.  Over the...
Beijing Invites to Taste Some of its Authentic Food Preparations
May 28, 2015  
The culinary profile of Beijing has been changed substantially over the last decade, which has given prime focus on the genuine culinary experiences and a bit less on the formal way of fine dining. According to Chief Executive Officer of the Rosewood Hotel Group, Sonia Cheng and also a native of Beijing stated that the direction that they are following currently is towards authentic, smaller,...
Where Does All the Food Go From Our Beloved Show Master Chef?
May 28, 2015  
Most of the countries enjoy the great food show held in Australia; however, most of the audience must be thinking about what the whole crew does with the remaining food every day. An answer to this turns out to be that, the whole fresh produce that the audience sees in the amazing jam-packed pantry is delivered to the SecondBite, which is a charity that makes provisions to provide nutritious...
New Trend Ushered in Europe to See Funds Firms Become Bank in All Respect But the Name
May 28, 2015  
According to analysts, Symon Drake-Brockman hailing from Australia is on the forefront of the revolution which is about to take the European finance industry by storm. The former head honcho in the debt markets department at Royal Bank of Scotland, Symon Drake-Brockman has now taken over the realms of Pemberton Asset Management located at the genteel community of Belgravia in London. ...